In the phase 3 ADMIRAL trial, 371 adult patients with relapsed or refractory FLT3-mutated AML were randomly assigned in a 2:1 ratio to receive either gilteritinib or salvage chemotherapy. This evidence concerns the gene FLT3 and acute myeloid leukemia.